Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

May 15, 2023 · Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth. Zacks Equity Research ... NVO . NVS . Eli Lilly and Company LLY boasts a solid portfolio of core drugs in …

CouponFollow Extension

7%
OFF

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key To Growth

3 weeks from now

May 15, 2023 · Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth. Zacks Equity Research ... NVO . NVS . Eli Lilly and Company LLY boasts a solid portfolio of core drugs in …

yahoo.com

7%
OFF

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key To Growth

3 weeks from now

Lilly announced mixed first-quarter 2023 results last month. It missed estimates for earnings but beat the same for sales. Its sales declined 11% year over year due to a significant fall in revenues from COVID-19 antibodies. However, excluding COVID-19 antibodies, revenue rose 10% on the back of volume growth from Mounjaro, Trulicity, Verzenio and ...

zacks.com

7%
OFF

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key To Growth

3 weeks from now

May 15, 2023 · Its revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. ... Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth ... the loss of …

nasdaq.com

24%
OFF

Eli Lilly Has A New Drug That Could Push The Stock Higher

3 weeks from now

Jun 20, 2024 · The stock of Eli Lilly (LLY-0.24%), the world's largest pharmaceutical company, keeps reaching new all-time highs, largely off the back of its weight loss and diabetes drugs, …

fool.com

7%
OFF

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key To Growth

3 weeks from now

May 15, 2023 · Eli Lilly and Company LLY boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Its revenue growth is being driven by higher demand for …

tradingview.com

75%
OFF

Eli Lilly And Co (LLY) Performance History & Total Returns

3 weeks from now

Jan 24, 2024 · The total return for Eli Lilly and Co (LLY) stock is 24.75% over the past 12 months vs. 27.37% for the S&P 500. ... What is the YTD total return for Eli Lilly and Co (LLY)? ... Novo …

financecharts.com

44%
OFF

Eli Lilly Stock Tumbles On Slower-Than-Expected Weight Loss Drug …

3 weeks from now

Jan 18, 2025 · The new forecast from Lilly reflects 44% year-over-year revenue growth for the fourth quarter and 32% for the year. So the company is still seeing strong growth -- just not as …

fool.com

$720
OFF

Eli Lilly Stock Could Have A Huge Growth Catalyst In Early 2025

3 weeks from now

Dec 12, 2024 · Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.

yahoo.com

000%
OFF

LLY Stock Price Quote - Morningstar

3 weeks from now

4 days ago · FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000% MarketWatch Jan 14, 2025 7:46pm Mounjaro and Zepbound sales disappoint, and Eli …

morningstar.com

$2
OFF

Eli Lilly Stock Tumbles On Lowered Guidance As Weight-Loss Drug …

3 weeks from now

Jan 14, 2025 · The race to develop new weight-loss drugs has been heating up. LLY Stock Technical Ratings Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer …

investors.com

$45
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

3 weeks from now

Jan 14, 2025 · 2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance. Q4 2024 revenue is expected …

lilly.com

40%
OFF

Eli Lilly Stock's Correction Brings Opportunity (NYSE:LLY)

3 weeks from now

2 days ago · Occupying over 40% of a fast-growing weight loss drug market, Eli Lilly and Company (NYSE:LLY) stock has been growing at a CAGR of over 30% since 2015 to its ATH …

seekingalpha.com

1%
OFF

What Does The Future Hold For Eli Lilly? - Nasdaq

3 weeks from now

3 days ago · Though the stock is up 25.1% in the year leading to January 24, 2025, in the back half of that time period—the six months from late July 2024 through January—LLY has …

nasdaq.com

FAQs about Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth Coupon?

Is Eli Lilly a good stock to buy?

Eli Lilly and Company LLY boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Its revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. However, its new and potential drug launches have been attracting investors to the stock. ...

Is Eli Lilly's stock correction ending?

Summary I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation multiples are justified by robust growth prospects in FY2025 and FY2026 (likely beyond that as well). ...

Will Eli Lilly's weight loss drug sales continue to grow in Q3?

Eli Lilly's weight loss drug sales in Q3 weren't as strong as it anticipated. Its earnings will continue to grow at a rapid pace regardless. It still has a couple of levers it can pull to drive more growth. Conditions are getting a bit more challenging for the drugmaker. ...

Why is Lilly a good stock to buy in 2023?

However, its new and potential drug launches have been attracting investors to the stock. Here we discuss the factors that are driving Lilly’s stock higher and can keep the positive momentum alive in 2023. The stock has risen 18.7% this year so far compared with an increase of 3.1% for the industry. ...

What was the total return for Eli Lilly & Co (LLY)?

The 20 year total return for LLY stock is 2,511.33%. What was the total return for Eli Lilly and Co (LLY) in 2024? The total return for LLY stock in 2024 was 33.30%. What was the total return for Eli Lilly and Co (LLY) in 2023? The total return for LLY stock in 2023 was 60.91%. What was the total return for Eli Lilly and Co (LLY) in 2022? ...

How many new medicines will Lilly launch by 2023?

Lilly expects to launchfour new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched. Mounjaro (tirzepatide) is already generating impressive sales, benefiting from strong demand trends. ...